Current Edition

biotech

Totus tots up $40M in series A funding to go after competitive cancer space

Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to …

Continue Reading →